

10 ml size, dried

List No. KD 060-610

ANTIHAEMOPHILIC FACTOR (HUMAN) HEMOFIL® HT **Method Four**

Heat Treated

Contents: One bottle 10 ml dried Antihaemophilic Factor (Human), one bottle 10 ml Water for Injections Ph. Eur., one syringe of 10 ml, one syringe needle (21 GA), one double-ended needle, one filter spike, one miniset (21 GA) and directions for use.

FOR INTRAVENOUS ADMINISTRATION.

Administration: See enclosed direction sheet and use as directed by physician.

Stabilised with heparin, not over 1.0 unit (0.010 mg) per ml of reconstituted material. Contains no preservative. Use promptly (within 3 hours) after reconstitution. Do not use if gel forms on reconstitution.


WARNING: Plasma from which this product was derived was found to be nonreactive for hepatitis B surface antigen (HB_sAg) when tested with

nonreactive for nepatitis B surface antigen (HB_sAg) when tested with licenced third generation reagents. In addition, the process used in the manufacture of this product includes a heating step designed to minimise the risk of transmission of hepatitis. However, no procedure has been shown to be totally effective in remo-ving hepatitis infectivity from Antihaemophilic Factor (Humań). The product and/or its manufacture is covered by Great Britain Patent 1,372,515. * Registered Trademark

Distributed by: TRAVENOL LABORATORIES LTD., Thetford, Norfolk, England.

POM PL0116/0150 PA167/7/8

30-6D-02-660A



OL STORE THIS PACKAGE BETWEEN 2 AND 8° C or up to 1 month (within dating period) at room temperature, not to exceed 25° C. Avoid freezing, which might damage diluent bottle. Protect from light. Date stored at room temperature :. This lot contains International Units of AHF activity per vial. 260 Lot No.: 860621A370A JUN. 88 Expiry Date: 30 10 86 GRO-C

List No. KD 060-610

10 ml size, dried

Method Four

(HUMAN) TH ®JIIOM∃H

*Α***ΝΤΙΗΑΕΜΟΡΗΙLIC FACTOR**

Heat Treated



10 ml size, dried

List No. KD 060-610

ANTIHAEMOPHILIC FACTOR (HUMAN) **HEMOFIL® HT Method Four**

Heat Treated

Contents: One bottle 10 ml dried Antihaemophilic Factor (Human), one bottle 10 ml Water for Injections Ph. Eur., one syringe of 10 ml, one syringe needle (21 GA), one double-ended needle, one filter spike, one miniset (21 GA) and directions for use.

FOR INTRAVENOUS ADMINISTRATION.

Administration: See enclosed direction sheet and use as directed by physician.

Stabilised with heparin, not over 1.0 unit (0.010 mg) per ml of recon-stituted material. Contains no preservative. Use promptly (within 3 hours) after reconstitution. Do not use if gel forms on reconstitution.

WARNING: Plasma from which this product was derived was found to be nonreactive for hepatitis B surface antigen (HBsAg) when tested with licenced third generation reagents.

In addition, the process used in the manufacture of this product includes a heating step designed to minimise the risk of transmission of hepatitis. However, no procedure has been shown to be totally effective in removing hepatitis infectivity from Antihaemophilic Factor (Human).

Distributed by: TRAVENOL LABORATORIES LTD., Thetford, Norfolk, England.

POM PL0116/0150 PA167/7/8

30-6D-02-660A

SHPL0001013_004_0004

GRO-C

dem le sou té

Lot No.: Expiry Date: 260 International Units of AHF activity per vial.

This lot contains

Date stored at room temperature:

860621A370A

STORE THIS PACKAGE BETWEEN 2 AND 8° C or up to 1 month (within dating period) at room temperature, not to exceed 25° C. Avoid freezing, which might damage diluent bottle. Protect from light.



List No. KD 060-610

10 ml size, dried ANTIHAEMOPHILIC FACTOR

Method Four

(HUMAN) TH [®]HT

Heat Treated